RE:Not sure I wanted to bring this topic up (again.)Per the latest annual meeting notice insiders own 19 million shares, plus 18 million stock options, CEO/CFO own a lot of warrants. In total insiders own maybe 15% on a fully diluted basis.
The issue I see with a low ball take out offer is that there are more than one big pharma watching here. Say big pharma company publicly offers $1/sh that's only $330 million for technology that could and probably will be worth tens of billions given a few more years time and trials. The rest of big pharma isn't going to just watch this get taken out like that. If an offer were made I won't be selling on the first offer.
On another note, there's 10 million executive/director options at 25 cents expiring September 11, 2024.
The 57 million warrants expiring this August are priced at 35 cents.
239 million shares outstanding,
87 million warrants outstanding, 67 million warrants expire in Aug/Sep
18 million options outstanding, 10 million expire in September
334 million fully diluted.